"Most patients with these severe outcomes had evidence of advanced cirrhosis prior to initiating therapy," Jackie Finley, a spokeswoman for AbbVie, wrote in an e-mail. "Estimates of frequency cannot be made and a causal relationship between treatment and these events has not been established."
Market Data 
Markets 
AI
